<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="232841">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00044720</url>
  </required_header>
  <id_info>
    <org_study_id>0468H1-101164</org_study_id>
    <nct_id>NCT00044720</nct_id>
  </id_info>
  <brief_title>Study Evaluating Sirolimus in End Stage Renal Disease in High Risk Kidney Transplant Recipients</brief_title>
  <official_title>An Open-label, Concentration Controlled, Randomized, 12 Month Study of Prograf + Rapamune + Cor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <brief_summary>
    <textblock>
      The incidence of efficacy failure at 12 months between two regimens.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">July 2005</completion_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <masking>Open Label</masking>
  </study_design_info>
  <enrollment type="Actual">484</enrollment>
  <condition>Chronic Kidney Failure</condition>
  <condition>Graft vs Host Disease</condition>
  <condition>Kidney Transplantation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rapamune</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Age: 13 years or older, 40 kgs or more

          -  End-stage renal disease

          -  African-American/Black transplant recipient and/or repeat renal transplant recipient
             who lost a previous allograft

        Exclusion Criteria

          -  Evidence of active infection

          -  Evidence abnormal chest x-ray

          -  Patients with HIV.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor, MD</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>August 2009</verification_date>
  <lastchanged_date>August 17, 2009</lastchanged_date>
  <firstreceived_date>September 4, 2002</firstreceived_date>
  <keyword>Kidney Transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
